up-front ibrutinib versus fcr for patients with cll
Published 4 years ago • 288 plays • Length 9:03Download video MP4
Download video MP3
Similar videos
-
1:44
ibrutinib and fcr in cll irrespective of ighv mutation status
-
1:17
dr. davids on ibrutinib plus fcr in younger patients with cll
-
3:12
ibrutinib and rituximab shows superior pfs vs. fcr in cll
-
5:00
upfront ibrutinib in cll
-
1:28
frontline ibrutinib-fcr for younger cll patients: phase ii results
-
3:19
patient selection for upfront ibrutinib
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
3:48
ibrutinib fcr or duvelisib fcr in the front line setting for high-risk cll patients
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
2:01
fcr or fr – which regimen is better for treating cll?
-
5:10
ibrutinib vs chlorambucil in cll patients not suitable for chemotherapy
-
1:42
ibrutinib and fcr chemoimmunotherapy: improving complete remission in cll patients?
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
1:33
dr. jennifer brown on fcr and ibrutinib in cll
-
1:29
dr. james on update of ibrutinib for chronic lymphocytic leukemia
-
11:28
adverse events of ibrutinib in chronic lymphocytic leukemia
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
4:25
ash 2018: ibrutinib-based therapy versus fcr in untreated patients with cll
-
2:51
ibrutinib-based therapy superior for younger patients with previously untreated cll compared wit...